Results of First Human Study of NMN Administration Reveal No Safety Concerns

Results of First Human Study of NMN Administration Reveal No Safety Concerns

Scientists from Keio University School of Medicine in Japan publish first study evaluating safety of nicotinamide mononucleotide (NMN) administration in humans, showing no adverse health concerns.

Date:
Share:
FULL STORY
STORY SOURCE
  1. Junichiro Irie, Emi Inagaki, Masataka Fujita, Hideaki Nakaya, Masanori Mitsuishi, Shintaro Yamaguchi, Kazuya Yamashita, Shuhei Shigaki, Takashi Ono, Hideo Yukioka, Hideyuki Okano, Yo-ichi Nabeshima, Shin-irchiro Imai, Masato Yasui, Kazuo Tsubota, Hiroshi Itoh.  Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese menEndocr J, 2019; DOI: 10.1507/endocrj.EJ19-0313.
JOURNAL REFERENCES
  1. Alessia Grozio, Kathryn F. Fills, Jun Yoshino, Santina Bruzzone, Giovanna Sociali, Kyohei Tokizane, Hanyue Cecilia Lei, Richard Cunningham, You Sasaki, Marie E. Migaud, Shin-ichiro Imai.  Slc12a8 is a nicotinamide mononucleotide transporterNat Metab, 2019; DOI: 10.1038/s42255-018-0009-4.
  2. Kazuhiro Hasegawa, Shu Wakino, Petra Simic, Yusuke Sakamaki, Hitoshi Minakuchi, Keiko Fujimura, Kozi Hosoya, Motoaki Komatsu, Yuka Kaneko, Takeshi Kanda, Eiji Kubota, Hirobumi Tokuyama, Koichi Hayashi, Leonard Guarente, Hiroshi Itoh.  Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytesNat Med, 2013; DOI: 10.1038/nm.3363.
  3. Junichiro Irie, Emi Inagaki, Masataka Fujita, Hideaki Nakaya, Masanori Mitsuishi, Shintaro Yamaguchi, Kazuya Yamashita, Shuhei Shigaki, Takashi Ono, Hideo Yukioka, Hideyuki Okano, Yo-ichi Nabeshima, Shin-irchiro Imai, Masato Yasui, Kazuo Tsubota, Hiroshi Itoh.  Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese menEndocr J, 2019; DOI: 10.1507/endocrj.EJ19-0313.
  4. Jonathan B. Lin, Shunsuke Kubota, Norimitsu Ban, Mitsukuni Yoshida, Andrea Santeford, Abdoulaye Sene, Rei Nakamura, Nicole Zapata, Miyuki Kubota, Kazuo Tsubota, Jun Yoshino, Shin-ichiro Imai, Rajendra S. Apte.  NAMPT-Mediated NAD+ Biosynthesis Is Essential for Vision in MiceCell Rep, 2016; DOI: 10.1016/j.celrep.2016.08.073.
  5. Kathryn F. Mills, Shohei Yoshida, Liana R. Stein, Alessia Grozio, Shunsuke Kubota, Yo Sasaki, Philip Redpath, Marie E. Migaud, Rajendra S. Apte, Koji Uchida, Jun Yoshino.  Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in MiceCell Metab, 2016; DOI: 10.1016/j.cmet.2016.09.013.
  6. Jun Yoshino, Kathryn F. Mills, Myeong Jin Yoon, Shin-ichiro Imai.  Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age- Induced Diabetes in MiceCell Metab, 2011; DOI: 10.1016/j.cmet.2011.08.014.